



**Health, Seniors and Active Living**  
Population and Public Health  
4<sup>th</sup> Floor; 300 Carlton Street  
Winnipeg MB R3B 3M9  
Email: [vaccines@gov.mb.ca](mailto:vaccines@gov.mb.ca)



**Santé, Aînés et Vie active**  
Population et santé publique  
4<sup>e</sup> étage; 300, rue Carlton  
Winnipeg MB R3B 3M9  
Email : [vaccines@gov.mb.ca](mailto:vaccines@gov.mb.ca)

November 14, 2020

Dear Health Care Provider:

**Urgent Action Required: FluLaval Tetra Vaccine Lot Number KX9F7**

The Public Health Agency of Canada has notified Manitoba Health, Seniors and Active Living that New Brunswick Public Health has initiated a vaccine safety investigation involving FluLaval Tetra Influenza vaccine lot number KX9F7.

Manitoba has received and distributed 64,030 doses of FluLaval Tetra vaccine with the lot number KX9F7 between October 22, 2020 and November 11, 2020 to providers across the province.

To date, Manitoba Health has not received any reports of serious adverse events following immunization with FluLaval Tetra Lot Number KX9F7.

As a precaution:

- Do not administer FluLaval Tetra vaccine with lot number KX9F7;
- Check your vaccine supply for FluLaval Tetra vaccine with lot number KX9F7 and mark 'DO NOT USE'
- Maintain cold chain and store vaccine at 2-8 degrees to allow for possible future use;
- If required short term, reorder replacement influenza vaccine following the usual process.

While no specific action is required to follow up with individuals who have received FluLaval Tetra Lot KX9F7 please continue to report adverse events following immunization as per the User Guide for the Completion and Submission of an AEFI Reporting Form and using the AEFI Report found at: <https://www.gov.mb.ca/health/publichealth/cdc/div/aefi.html>.

If you have any questions please send to [vaccines@gov.mb.ca](mailto:vaccines@gov.mb.ca).

Sincerely,

Richard Baydack, PhD  
Director  
Communicable Disease Control

Tim Hilderan, MD FRCPC  
Medical Lead, Vaccines  
Communicable Disease Control